Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Aligos Therapeutics Inc
Healthcare
P/NCAV
0.66x
Ticker
ALGS
Exchange
NASDAQ
Country
United States
Close
0.84 $
Mkt Cap
53.7M $
EV
-81.8M $
NCAV Burn Rate
10.0%
Current Ratio
5.9
Debt/Equity
0.0
EV/REV
-5.27x
EV/EBIT
0.9x
EV/FCF
1.0x
Dilution
11.7% p.A
Total Net Income
-486.8M $
Cheapness
96.0%
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average